Filing Details
- Accession Number:
- 0001209191-20-007871
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-10 16:14:40
- Reporting Period:
- 2020-02-06
- Accepted Time:
- 2020-02-10 16:14:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1334365 | Yuchun Lee | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-02-06 | 2,000 | $57.27 | 3,875 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-02-06 | 1,071 | $238.71 | 2,804 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-06 | 400 | $239.28 | 2,404 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-06 | 429 | $240.65 | 1,975 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-06 | 100 | $244.08 | 1,875 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-02-06 | 2,000 | $0.00 | 2,000 | $57.27 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
16,306 | 2022-09-13 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $238.71 (range $238.15 to $239.13).
- Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $239.28 (range $239.20 to $239.45).
- Open market sales reported on this line occurred at a weighted average price of $240.65 (range $240.39 to $241.36).
- Fully vested.